(±)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: Studies in animals

Neuropsychobiology

Volumn 42, Issue 1, 2000, Pages 5-10

  Ricaurte, George A ^a,b   Yuan, Jie ^a   McCann, Una D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Amphetamines; MDMA; Monkeys; Neurotoxicity; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BRAIN MONOAMINE; SEROTONIN; SEROTONIN RECEPTOR AFFECTING AGENT;

ARTICLE; MONOAMINE RELEASE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SEROTONINERGIC NERVE CELL; SYNAPSE VESICLE; ANIMAL; DRUG EFFECT; METABOLISM; NERVE CELL; PATHOLOGY; REVIEW; TOXICITY AND INTOXICATION;

ANIMALS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURONS; NEUROTOXICITY SYNDROMES; SEROTONIN AGENTS;

EID: 0033623773     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026664     Document Type: Article

References (50)

1. Ricaurte GA, Bryan G, Strauss L, Seiden LS, Schuster CR: Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985;229:986-988.
2. Schmidt CJ, Wu L, Lovenberg W: Methylenedioxymethamphetamine: A potentially neurotoxic amphetamine analog. Eur J Pharmacol 1986;124:175-178.
3. Stone DM, Stahl DC, Hanson GR, Gibb JW: The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 1986; 128:41-48.
4. Commins DL, Vosmer G, Virus R, Woolverton W, Schuster C, Seiden L: Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987;241:338-345.
5. Schmidt CJ: Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 1987;240:1-7.
6. Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Molliver ME, et al: (±)3,4-Methylenedioxymethamphetamine (MDMA) selectively damages central serotonergic neurons in nonhuman primates. JAMA 1988;260: 51-55.
7. Slikker W, Ali SF, Scallet C, Frith CH, Newport GD, Bailey JR: Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 1988;94:448-457.
8. Insel RT, Battaglia G, Johannessen JN, Marra S, De Souza EB: 3,4-Methylenedioxymethamphetamine ('ecstasy') selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 1989;249:713-720.
9. Ali SF, Newport GD, Scallet AC, Binienda Z, Ferguson SA, Bailey JR, Paule MG, Slikker W Jr: Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Neurotoxicol Teratol 1993;15:91-96.
10. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Raven HT, Szabo K, Yuan J, Ricaurte GA: In vivo detection of short- and long-term MDMA neurotoxicity. A positron emission tomography study in the living baboon brain. Synapse 1998;29:183-192.
11. Aguirre N, Barrionuevo M, Lasheras B, DelRio J: The role of dopaminergic systems in the perinatal sensitivity to 3,4-methylenedioxymethamphetamine-induced neurotoxicity in rats. J Pharmacol Exp Ther 1998;286:1159-1165.
12. Holland J: Positron emission tomography findings in heavy users of MDMA. Lancet 1999; 353:592-593.
13. Battaglia G, Yeh SY, De Souza EB: MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 1988;29:269-274.
14. Ricaurte GA, Martello AL, Katz JL, Martello MB: Lasting of (±)3,4-methylenedioxymethamphetamine on central serotonergic neurons in non-human primates: Neurochemical observations. J Pharmacol Exp Ther 1992;261:616-622.
15. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA: Serotonergic recovery after (±)3,4-(methylenedioxy)methamphetamine injury: Observation in rats. J Pharmacol Exp Ther 1993;264:1484-1491.
16. Fischer CA, Hatzidimitriou G, Katz JL, Ricaurte GA: Reorganization of ascending serotonin axon projections in animals previously exposed to the recreational drug 3,4-methylenedioxymethamphetamine. J Neurosci 1995; 15:5476-5485.
17. Lew R, Sabol KE, Chou C, Vosmer GL, Richards J, Seiden LS: Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. II. Radioligand binding and autoradiography studies. J Pharmacol Exp Ther 1996;276: 855-865.
18. Sabol KE, Lew R, Richards JB, Vosmer GL, Seiden LS: Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Synaptosomal uptake and tissue concentrations. J Pharmacol Exp Ther 1996;276:846-854.
19. Hatzidimitriou G, McCann UD, Ricaurte GA: Altered serotonin innervation patterns in the forebrain of monkeys treated with (±)3,4-methylenedioxymethamphetamine seven years previously: Factors influencing abnormal recovery. J Neurosci 1999;191:5096-5107.
20. 3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1987;242:911-916.
21. Schmidt CJ, Taylor VL: Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 1987;36:4095-4102.
22. O'Hearn EG, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME: Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity. J Neurosci 1988;8:2788-2803.
23. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn EG, Wilson MA: Neurotoxicity of MDMA and related compounds: Anatomic studies. Ann NY Acad Sci 1990;600: 640-664.
24. Wilson MA, Ricaurte GA, Molliver ME: Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 1989;28: 121-137.
25. Wilson MA, Mamounas LA, Fasman KA, Axt KJ, Molliver ME: Reactions of 5-HT neurons to drugs of abuse: Neurotoxicity and plasticity. NIDA Res Monogr 1993;136:155-187.
26. Axt KJ, Mamounas LA, Molliver ME: Structural features of amphetamine neurotoxicity in the brain: in Cho A, Segal DS (eds): Amphetamine and its Analogs: Neuropsychopharmacology, Toxicology and Abuse. New York, Academic Press, 1994, pp 315-336.
27. McCann UD, Lowe KA, Ricaurte GA: Long-lasting effects of recreational drugs of abuse on the central nervous system. Neuroscientist 1997;3:399-411.
28. Naudon L, Leroux-Nicollet I, Constentin J: Short-term treatments with haloperidol or bromocryptine do not alter the density of the vesicular monoamine transporter. Neurosci Lett 1994;173:1-4.
29. Vander Borght T, Sima A, Kilbourn MR, et al: The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294:577-583.
30. Frey K, Kilbourne M, Robinson T: Reduced striatal vesicular monoamine transporter after neurotoxic but not after behaviourally-sensitizing doses of methamphetamine. Eur J Pharmacol 1997;334:273-279.
31. Frey K, Koeppe R, Kilbourn M, Vander Borght T, Albin R, Gilman S, Kuhl D: Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996;40:873-884.
32. Halaris A, Jones B, Moore R: Axonal transport in serotonin neurons of the midbrain raphe. Brain Res 1976;107:555-574.
33. Callahan BT, Hatzidimitriou G, Yuan J, Ricaurte GA: Long-term effects of substituted amphetamines on anterograde axonal transport from the rostral raphe nuclei. Soc Neurosci Abstr 1998;24:1735.
34. Jonsson G, Pollare T, Hallman H, Sachs C: Development plasticity of central serotonin neurons after 5,7-dihydroxytryptamine treatment. Ann NY Acad Sci 1978;305:328-345.
35. Schneider GF: Early lesions of the superior colliculus: Factors affecting the formation of abnormal retinal projections. Brain Behav Evol 1973;8:73-109.
36. Levitt P, Moore R: Organization of brainstem noradrenaline hyperinnervation following neonatal 6-hydroxydopamine treatment in the rat. Anal Embryol 1980;158:133-150.
37. Jonsson G, Sachs C: Changes in the development of central noradrenergic neurons after neonatal axon lesions. Brain Res Bull 1982;9: 641-650.
38. Gustafson E, Moore R: Noradrenaline neuron plasticity in developing rat brain: Effects of neonatal 6-hydroxydopamine demonstrated by dopamine-B-hydroxylase immunocytochemistry. Dev Brain Res 1987;37:143-155.
39. Fritschy J, Grzanna R: Restoration of ascending noradrenergic projections by residual locus coeruleus neurons: Compensatory response to neurotoxin-induced cell death in the adult rat brain. J Comp Neurol 1992;321:421-441.
40. Sachs C, Jonsson G: 5,7-dihydroxytryptamine induced changes in the postnatal development of central 5-hydroxytryptamine neurons. Med Biol 1975;53:156-164.
41. Wiklund L, Bjorklund A, Nobin A: Regeneration of serotonin neurons in the rat brain after 5,6-dihydroxytryptamine-induced axotomy. Ann NY Acad Sci 1978;305:370-384.
42. Bjorklund A, Wiklund L, Descarries L: Regeneration and plasticity of central serotonergic neurons: A review. J Physiol 1979;77:247-255.
43. Frankfurt M, Azmitia E: Regeneration of serotonergic fibers in the rat hypothalamus following unilateral 5,7-dihydroxytryptamine injection. Brain Res 1984;298:273-282.
44. Stone DM, Hanson GL, Gibb JW: Differences in the central serotonergic effects of 3,4-methylenedioxymethamphetamine(MDMA) in mice and rats. Neuropharmacology 1987;26:1657-1661.
45. Finnegan KT, Ricaurte GA, Ritchie CD, Irwin I, et al: Orally administered MDMA causes a long-term depletion of serotonin in rat brain. Brain Res 1988;447:141-144.
46. Ricaurte GA, DcLanney LE, Irwin I, Langston JW: Toxic effects of MDMA on central serotonergic neurons in the primate: Importance of route and frequency of drug administration. Brain Res 1988;446:165-168.
47. Mordenti J, Chappell W: The use of interspecies scaling in toxicokinetics: in Yacobi A, Kelly J, Batral V (eds): Toxicokinetics in New Drug Development. New York, Pergamon Press 1989, pp 42-96.
48. Chappell W, Mordenti J: Extrapolation of toxicological and pharmacological data from animals to humans; in Testa B (ed): Advances in Drug Research. San Diego, Academic Press, 1991, vol 20, pp 1-116.
49. O'Shea E, Granados R, Esteban B, Colado MI, Green AR: The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 1998;37:919-926.
50. Steele T, McCann U, Ricaurte G: 3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Pharmacology and toxicology in animals and humans. Addiction 1994;89:539-551.